Page 2 - Pharmaceutical Firms

BDR Pharma introduces prostate cancer drug with enhanced strength

The company has introduced the medication, under the brand name BDENZA 160mg, at Rs 6,300 for a strip of seven tablets

Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode

An official of Dr Reddy's Laboratories said they are closely monitoring the developments and ensuring the well-being of their staff in that region is the first and foremost priority

Zydus gets regulator nod to market generic diabetes drug in American

Zydus Group on Wednesday said it has received final approval from the US health regulator to market diabetes medication Dapagliflozin tablets in the American market. The drug maker has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 5 mg and 10 mg. Dapagliflozin is used with a proper diet and exercise programme to control high blood sugar in people with type 2 diabetes. The drug also lowers the risk of heart failure in adults with type 2 diabetes with heart disease. It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalisation for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, Zydus Group stated. The group now has 328 approvals and has so far fi

Macleods Pharma files DRHP for second largest IPO by drug co at Rs 5,000 cr

It is entirely an offer for sale or OFS, company won't receive any of the proceeds

Ipca Laboratories' PAT declines 26% to Rs 199.9 crore in December quarter

The company had posted a consolidated net profit of Rs 265.47 crore in the corresponding period last fiscal, Ipca Laboratories said in a regulatory filing

Natco Pharma consolidated net profit up 27% to Rs 80 crore in Dec quarter

The Hyderabad-based company had reported a net profit of Rs 63.4 crore in the October-December period of previous fiscal

Serum backed Mylab to make and sell Covid-19 vax, working on 2-3 platforms

Partners with Shilpa Medicare to manufacture vaccines, therapeutics

Price erosion in US drags Alembic Pharma's Q3 net down 40% to Rs 176 cr

While the firm's US business fell 23% to Rs 393 cr in Q3FY22, its API sales were down 7% to Rs 198 crore

Pfizer to rake in earnings of over $100 bn in Covid vax & antiviral pill

On Tuesday, the company revealed its fourth quarter earnings and revenue projections for 2022 where it said it estimates it will earn up to $102 billion in sales next year, which would be a new record

GSK Pharma's net profit falls 3.9% to Rs 150.3 cr in December quarter

The company had posted a consolidated net profit of Rs 156.51 crore in the corresponding quarter last fiscal, GlaxoSmithKline Pharmaceuticals said in a regulatory filing

Brinton Pharma to launch generic version of anti-Covid pill Molnupiravir

The company will introduce it in the domestic market under the brand 'Molviton'

Moderna slump hits 50% from peak, erasing $98 billion value

Moderna's shares were pressured as coronavirus pills by Pfizer and Merck & Co recently received FDA authorisation

E-commerce, pharma sector to revive demand for packaging paper: CRISIL

A strong revival in consumer spending amid waning impact of the Covid-19 pandemic will help the paper packaging industry bounce back with a revenue growth of 15% this fiscal

Lupin to set up 100 diagnostic labs and 1,000 collection centres in 5 yrs

Announced foray into fragmented diagnostic business where organised chains have less than 20% share of overall business

Glenmark, Alembic, Cipla: Pharma stocks on a booster dose this December

Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears of Omicron variant spreading may also keep them in news and buzzing

Moderna CEO says vaccines likely less effective against Omicron: Report

'There is no world, I think, where (the effectiveness) is the same level we had with Delta,' Stephane Bancel told the Financial Times.

Without innovation Indian pharma cannot touch $130 bn by 2030: Industry

Sun Pharma says it eyes $1.5 bn from innovative products in 3-4 years

US-based Amneal Pharmaceuticals acquires Puniska Healthcare for Rs 700 cr

US-based Amneal Pharmaceuticals Inc on Tuesday said it has acquired Ahmedabad-based drug firm Puniska Healthcare Pvt Ltd for a total value of around Rs 700 crore. The acquisition significantly enhances Amneal's injectables manufacturing infrastructure, capabilities, and capacity to support the US market and serve as a foundation for international markets, the company said in a statement. Puniska includes a 293,000 square foot, manufacturing facility in Ahmedabad, with a number of sterile injectable production lines. Production capabilities include robotic, aseptic and lyophilize vial lines, emulsion line, and large-volume parenteral bag line, it added. The acquisition also brings to the company approximately 550 Puniska employees with key capabilities in injectables manufacturing, R&D and commercialisation, Amneal said. "This acquisition is a pivotal step that meaningfully enhances our injectables capabilities for the US market and enables international expansion, including in ...

AstraZeneca Pharma India Q2 net profit declines 55% to Rs 12 crore

The drug firm on Tuesday reported a 54.65 per cent decline in its net profit

Cadila Healthcare Q2 PAT up by 6% YoY to Rs 597 cr, revenue up 3%

The company's EBIDTA margin for the quarter was 22.7 per cent, up by 50 basis points